Medical Inspection – Health Blog

The novel metabotropic glutamate receptor 5 negative allosteric modulator ADX10059 has been shown to reduce reflux and esophageal acid exposure in both healthy individuals and patients with GERD. Zerbib and colleagues presented results from a double-blind, placebo-controlled, multicenter trial evaluating the effects of single-agent ADX10059 on symptom control in patients with GERD. The study enrolled [...]

A study evaluated the effects of DEX on quality of life and symptom severity in patients with symptomatic nonero-sive GERD. In the initial 4-week study, 313 patients (mean age, 49.4 years; 69.3% women) initially received DEX 60 mg, 90 mg, or placebo once daily. In the subsequent multicenter, open-label, 12-month safety study, patients were randomly [...]

Benefit of Dexlansoprazole or Lansoprazole Maintained After Discontinuation To evaluate the incidence of acid or symptom rebound following discontinuation of dexlansoprazole MR (DEX; Dexilant, Takeda) or lansoprazole (LAN), an analysis was undertaken evaluating outcomes in patients with Helicobacter pylori—negative erosive esophagitis (EE) enrolled in clinical trials who attained healing after 4 or 8 weeks of [...]

Combination PI-Containing Regimen for HIV-Infected, Treatment-Experienced Patients Speaker: Robert Schooley, MD, Head of Infectious Diseases and Professor of Medicine, University of Colorado, Denver, Colorado. Based on a preliminary 24-week analysis, amprenavir 600 mg (Agenerase, GlaxoSmithKline)/ritonavir 100 mg (Norvir drug, Abbott) twice daily might be a better treatment regimen than amprenavir 900 mg/ritonavir 100 mg twice [...]

Speaker: Steven P. LaRosa, MD, Associate Staff Physician, Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, Ohio. Drotreogin alfa activated (Xigris, Lilly), a recombinant form of protein C recently approved by the FDA for the treatment of severe sepsis, markedly reduces the risk of all-cause mortality in adult patients, according to findings from the PROWESS [...]

Speaker: Joseph L. Gugliotta, MD, Infectious Disease Specialist, Hunterdon Medical Center, Flemington, New Jersey. The combination of quinupristin/dalfopristin (Synercid, Aventis) and vancomycin (Vancocin, Lilly) proved to be highly effective in the treatment of bacteremias caused by oxacillin-resistant Staphylococcus aureus (ORSA) strains, demonstrating enhanced bactericidal activity compared with either antibiotic tested alone.

Short-Duration Antimicrobial Therapy for AECB Speaker: Marcus J. Zervos, MD, Clinical Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan, and William Beaumont Hospital, Royal Oak, Michigan. Five-day therapy with oral telithromycin (Ketek, Aventis), a new ketolide antimicrobial agent, is as effective as standard 10-day treatment with comparators in adult patients with acute [...]